Sigyn Therapeutics, Inc. (SIGY): Cash & Equivalents
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$12.1K
As of 2024-12-31
$85.6K
As of 2025-09-30
-67.1%
3-year compound annual growth
+89.3%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $12.1K | +3.9% | 2025-04-15, Balance as of period end |
| 2023-12-31 | $11.7K | +39.9% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $8.4K | -97.5% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $341.0K | +304.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $84.4K | n/m | 2022-03-21, Balance as of period end |
| 2019-12-31 | $500 | -93.3% | 2020-03-30, Balance as of period end |
| 2018-12-31 | $7.5K | -21.8% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $9.6K | n/a | 2019-04-01, Balance as of period end |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $638.8K | n/m | 2016-03-30, Balance as of period end |
| 2014-12-31 | $95 | n/a | 2016-03-30, Balance as of period end |